PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors

References

• Klöppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med. 2017;33(5):324–333. doi:10.1159/000481390.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs (Vol. 10). Lyon: IARC Press; 2017.
   Google Scholar
• Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev. 50:61–67. doi:10.1016/j.ctrv.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller -H-H, Arnold R. 2017. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 104:26–32. doi:10.1159/000443612.
   PubMed Web of Science ®Google Scholar
• Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557–577. doi:10.1097/MPA.0b013e31828e34a4.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, et al. 2016. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 387:968–977. doi:10.1016/S0140-6736(15)00817-X.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11(10):702–711. doi:10.1038/nri3064.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73. doi:10.1016/j.immuni.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. 2012. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012:492920. doi:10.1155/2012/492920.
   PubMedGoogle Scholar
• Turner HE, Harris AL, Melmed S, Wass JAH. Angiogenesis in endocrine tumors. Endocr Rev. 2003;24(5):600–632. doi:10.1210/er.2002-0008.
   PubMed Web of Science ®Google Scholar
• Terris B, Scoazec J, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Fléjou J, Degott C. Expression of vascular. endothelial growth factor in digestive neuroendocrine tumors. Histopathology. 1998;32(2):133–138.
   PubMed Web of Science ®Google Scholar
• Schnirer II, Yao JC, Ajani JA. Carcinoid–a comprehensive review. Acta Oncol. 2003;42(7):672–692.
   PubMed Web of Science ®Google Scholar
• Scoazec JY. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology. 2013;97(1):45–56. doi:10.1159/000338371.
   PubMed Web of Science ®Google Scholar
• Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am. 2007;21(3):433–455. doi:10.1016/j.hoc.2007.04.004.
   PubMed Web of Science ®Google Scholar
• Couvelard A, O’Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, et al.. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92(1):94–101. doi:10.1038/sj.bjc.6602245.
   PubMed Web of Science ®Google Scholar
• Marion-Audibert AM1, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle J-A, et al.. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology. 2003;125(4):1094–1104.
   PubMed Web of Science ®Google Scholar
• La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol. 2003;34(1):18–27. doi:10.1053/hupa.2003.56.
   PubMed Web of Science ®Google Scholar
• Zhang J1, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey J-N, Xie K, Yao JC. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007;109(8):1478–1486. doi:10.1002/cncr.22554.
   PubMed Web of Science ®Google Scholar
• Besig S, Voland P, Baur DM, Perren A, Prinz C. Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology. 2009;90(4):402–415. doi:10.1159/000245900.
   PubMed Web of Science ®Google Scholar
• Merla A, Goel S. Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract. 2012;2012:387172.
   PubMedGoogle Scholar
• Inanç M, Er O, Karaca H, Berk V, Ozkan M, Saraymen R, Elmalı F. factor levels during chemotherapy in patients with metastatic colorectal cancer. Med Oncol. 2012;29(5):3119–3124. doi:10.1007/s12032-012-0250-8.
   PubMed Web of Science ®Google Scholar
• Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod. 2006 Jan;21(1):262–268. doi:10.1093/humrep/dei308.
   PubMed Web of Science ®Google Scholar
• Choudhury GG, Grandaliano G, Jin DC, Katz MS, Abboud HE. Activation of PLC and PI 3 kinase by PDGF receptor alpha is not sufficient for mitogenesis and migration in mesangial cells. Kidney Int. 2000 Mar;57(3):908–917. doi:10.1046/j.1523-1755.2000.00907.x.
   PubMed Web of Science ®Google Scholar
• Mehrotra M, Krane SM, Walters K, Pilbeam C. Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem. 2004 Nov 1;93(4):741–752. doi:10.1002/jcb.20138.
   PubMed Web of Science ®Google Scholar
• Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat. 1993;26(3):247–252.
   PubMed Web of Science ®Google Scholar
• Takanami I, Imamura T, Yamamoto Y, Kodaira S. Usefulness Usefulness of platelet-derived growth factor as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol. 1995;58(1):40–43.
   PubMed Web of Science ®Google Scholar
• Herraiz C, Jiménez-Cervantes C, Sánchez-Laorden B, García-Borrón J. Functional interplay between secreted ligands and receptors in melanoma. Semin Cell Dev Biol. 2018;78:73–84.
   PubMed Web of Science ®Google Scholar
• Manzat-Saplacan RM, Balacescu L, Gherman C, Visan S, Chira RI, Bintintan A, Nagy G, Popovici C, Valean SD, Anca C, et al. Is there a correlation between peripheral blood expression of angiogenic transcriptional factors/receptors and colorectal cancer? J BUON. 2015;20(5):1193–1200.
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR, Fidler IJ. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer. 2006;119(11):2567–2574. doi:10.1002/ijc.22229.
   PubMed Web of Science ®Google Scholar
• Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19(8):460–473. doi:10.1016/j.molmed.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14(3):285–294. doi:10.1177/107327480701400312.
   PubMedGoogle Scholar
• Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357–5364. doi:10.1200/JCO.2005.14.068.
   PubMed Web of Science ®Google Scholar
• Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostman A. 2009. Prognostic Significance of stromal platelet-derived growth factorβ- receptor expression in human breast cancer. Am J Pathol. 175:334–341. doi:10.2353/ajpath.2009.081030.
   PubMed Web of Science ®Google Scholar
• Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE. 2010. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 116:2984–2993. doi:10.1182/blood-2010-02-269894.
   PubMed Web of Science ®Google Scholar
• Beauchamp D, Coffey RJ Jr., Lyons RM, Perkett EA, Townsend CM Jr., Moses HL. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res. 1991;51:5253–5260.
   PubMed Web of Science ®Google Scholar
• Chaudhry RA, Funa K, Oberg K. 1993. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 32:107–114. doi:10.3109/02841869309083898.
   PubMed Web of Science ®Google Scholar
• Pietras K1, Sjöblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell. 2003 May;3(5):439–443.
   PubMed Web of Science ®Google Scholar
• Bartoschek M, Pietras K. PDGF family function and prognostic value in tumor biology. Biochem Biophys Res Commun. 2018 Jun 22;S0006-291X(18)31418–9. doi:10.1016/j.bbrc.2018.08.050.
   PubMed Web of Science ®Google Scholar
• Schneider L, Clement CA, Teilmann SC, Pazour GJ, Hoffmann EK, Satir P, Christensen ST. PDGFRalpha signaling is regulated through the primary cilium in fibroblasts. Curr Biol. 2005 Oct 25;15(20):1861–1866. doi:10.1016/j.cub.2005.09.012.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al.. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–710. doi:10.1126/science.1079666.
   PubMed Web of Science ®Google Scholar
• Knösel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I. High High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. J Cancer Res Clin Oncol. 2012;138(3):397–403. doi:10.1007/s00432-011-1107-9.
   PubMed Web of Science ®Google Scholar
• Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic evaluation of 62 cases. Cancer. 1971;28(4):990–998.
   PubMed Web of Science ®Google Scholar
• Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008 Jan 29;5(1):e19. doi:10.1371/journal.pmed.0050019.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Hamashima T, Yamamoto S, Sasahara M. 2017. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor. Pathol Int. 67:235–246. doi:10.1111/pin.12530.
   PubMed Web of Science ®Google Scholar
• Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014;25(3):273–283. doi:10.1016/j.cytogfr.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Huijbers EJ, vanBeijnum JR, Thijssen VL, Sabrkhany S, Nowa Sliwinska P, Griffioen AW. 2016. Role of the tumor stroma in resistance to anti angiogenic therapy. Drug Resist Updates. 25:26–37. doi:10.1016/j.drup.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027. doi:10.1200/JCO.2005.06.081.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403. doi:10.1038/nrd.2015.17.
   PubMed Web of Science ®Google Scholar
• Chan JA, Kulke MH. Medical management of pancreatic neuroendocrine tumors: current and future therapy. Surg Oncol Clin N Am. 2016;25(2):423–437. doi:10.1016/j.soc.2015.11.009.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, et al.. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–2012. doi:10.1016/S0140-6736(11)61742-X.
   PubMed Web of Science ®Google Scholar
• Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy Angiogenesis. Angiogenesis. 2017;20(2):185–204. doi:10.1007/s10456-017-9552-y.
   PubMed Web of Science ®Google Scholar
• Benias PC, Wells RG3, Sackey-Aboagye B, Klavan H, Reidy J, Buonocore D, Miranda M, Kornacki S, Wayne M, Carr-Locke DL, et al. Structure and distribution of an unrecognized interstitium in human tissues. Sci Rep. 2018 Mar 27;8(1):4947. doi:10.1038/s41598-018-23062-6.
   PubMedGoogle Scholar
• Cavalcanti E, Armentano R, et al. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8(8):e3004.
   PubMedGoogle Scholar
• Einstein DJ, McDermott DF. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer. Clin Adv Hematol Oncol. 2017;15(6):478–488.
   PubMed Web of Science ®Google Scholar